AAAram Aslanyan

Aram Aslanyan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Aram Aslanyan has a total of 82 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Spatiotemporal characterization of Alzheimer disease pathology in living human brain tissue

    by Aram Aslanyan, Soumya Mukherjee, Eleanor M. Moncur, Alicja Szadziewska, Yingxin He, Przemysław R. Kac, Reid Coyle, Elena Camporesi, Chihiro Sato, Nupur Ghoshal, et al.

    Alzheimer disease begins in the brain many years before symptoms, but early changes are usually studied after death or indirectly through fluid and imaging biomarkers. Here we show that small brain biopsies collected during ventriculoperitoneal shunt surgery can be used to study Alzheimer disease pathology and protein turnover during life. We analysed biopsies from 18 individuals with suspected normal pressure hydrocephalus, alongside matched ventricular and lumbar cerebrospinal fluid and post-mortem control brain tissue. Amyloid plaques were present in 9 of 18 biopsies, while mature tau tangles were rare. Matrix-assisted laser desorption/ionization mass spectrometry imaging mapped amyloid plaque chemistry within tissue. Phosphorylated tau 217 was enriched around plaques, supporting a local relationship between amyloid and tau pathology. Stable isotope labelling, which tracks newly made proteins, detected rapid tau labelling within approximately 3 hours and estimated brain tau half-life at about 34 days. Amyloid plaques showed little detectable turnover.


  • Open Access

    Targeting tau in Alzheimer’s Disease: rationale, approach and challenges

    by Aram Aslanyan, Martha S. Foiani, Tatiana A. Giovannucci, Eric McDade, Karen E. Duff, Catherine J. Mummery, Michael Schöll, Kristin R. Wildsmith, Ross W. Paterson

    Alzheimer’s Disease (AD) is the most common neurodegenerative disorder and the leading cause of dementia characterised by the accumulation of beta amyloid (Aβ) plaques and neurofibrillary tangles (NFT). Several monoclonal antibodies against amyloid in early AD have shown the utility of reducing brain amyloid in large phase 3 studies, resulting in modest clinical benefit. To further slow, or even halt disease progression, targeting additional pathobiological pathways is likely to be necessary. In this review, we aim to appraise the scientific rationale for targeting tau in AD. The burden of tau pathology is correlated with disease severity and its role in AD progression is complex, involving synapse dysfunction, neuronal loss, neuroinflammation and autophagy impairment. Evidence suggests that hypersecretion, post-translational modifications and aggregation propensity, dependent and independent of amyloid, are also linked to neurodegeneration. We review the therapeutic agents in development including tau synthesis modifiers, active and passive immunotherapies, post-translational modifiers and aggregation inhibitors. Finally, we consider the available biomarker tools for patient selection and drug effectiveness evaluation, and we identify key knowledge gaps that future novel biomarkers might address to make clinical trials of tau therapies more likely to succeed.


  • Open Access

    CSF protein clearance impairment revealed using stable isotope kinetics in normal pressure hydrocephalus

    by Claire A Leckey, Tatiana A Giovannucci, Eimear C Murphy, Eleanor M Moncur, Kanza Tariq, Aram Aslanyan, Michael Schöll, Meera Srikrishna, William Coath, Suzanne Barker, et al.

    Normal pressure hydrocephalus is a common cause of gait and cognitive impairment in older adults, marked by excessive CSF accumulation. Genetic studies suggest impaired fluid clearance, and clinical symptoms can improve after CSF diversion. However, no fluid biomarkers exist to explore CSF accumulation mechanisms, assist diagnosis, or predict response to treatment. Stable isotope labelling kinetics is a clinical research tool that uses non-radioactive isotopes to label newly translated proteins, enabling measurement of their appearance (synthesis) and disappearance (clearance) in compartments like CSF. This study aimed to develop a novel method to capture protein turnover in CSF and assess whether clearance disruption is evident in normal pressure hydrocephalus with extended follow-up. Proteins of interest were identified via mass spectrometry in human CSF and choroid plexus organoid-derived CSF-like fluid. Protein origin and synthesis rates were evaluated by labelling organoids with 13C6-leucine. Label incorporation was measured using targeted mass spectrometry to determine the ratio of labelled to unlabelled peptide. A proof-of-concept case-control study was then conducted in specialist neuroscience centres. Participants received intravenous 13C6-leucine and underwent serial CSF withdrawal via lumbar drain, with matched blood sampling for up to 72 h. Patients undergoing CSF drainage and controls were recruited sequentially. Targeted mass spectrometry was used to determine protein production and clearance rates. To determine the clinical relevance of these protein turnover rates to CSF flow, they were correlated with direct measurements of CSF production captured using a LiquoGuard machine linked to the lumbar CSF drain. We captured choroid plexus protein kinetics in human organoids and the CSF of participants undergoing CSF drainage (n = 10) or controls (ventricular CSF n = 4; lumbar CSF n = 5). The case and control cohorts varied in sex (NPH = 80% male and controls = 22% male) and in age. There was no significant age difference between NPH and the lumbar control cohort (n = 5) (NPH: 75 (71–78) versus 70 (63–84) years old; P = 0.2438). We found that transthyretin is abundantly secreted by choroid plexus organoids, and observed correlations with CSF transthyretin synthesis rates and volume of CSF production in vivo (P = 0.738; P < 0.05). Clearance rates of transthyretin are ∼10 fold slower in normal pressure hydrocephalus compared with controls, suggesting impaired CSF protein clearance. This method is a novel clinical tool for interrogating CSF protein dynamics and may have utility in tracking CSF flow clinically.


  • Open Access

    In vivo amyloid and tau metabolism in human brain tissue

    by Aram Aslanyan, Soumya Mukherjee, Maciej Dulewicz, Reid Coyle, Yingxin He, Chihiro Sato, Nupur Ghoshal, Junyue Ge, Eleanor Moncur, Srinivas Koutarapu, et al.

    Background: Knowledge of the chemical composition of amyloid plaques and tau tangles at the earlier stages of Alzheimer’s disease (AD) pathology is sparse. This is due to limited access to human brain during life and at the earlier stages of AD pathophysiology and technical limitations in quantifying amyloid and tau species at a subcellular level. Understanding the chemical composition of plaques and tangles, how rapidly they grow and what factors drive growth is important for developing and refining therapeutics. We access in vivo cortical brain biopsy samples from individuals undergoing surgery, aiming to provide detailed characterisation of pathology with spatial and temporal resolution.Method: We collected in vivo brain biopsies with matched ventricular and lumbar cerebrospinal fluid samples from individuals with suspected Normal Pressure Hydrocephalus (NPH) undergoing ventriculoperitoneal shunt surgery. All participants were labelled with intravenous 13C6 Leucine as per Stable Isotope Labelling Kinetics protocol. We used immunohistochemistry, immunoprecipitation‐mass spectrometry (IP‐MS) and Matrix Assisted Laser Desorption Ionization (MALDI) mass spectrometry‐based imaging (MSI) to characterise amyloid and tau and their common post‐translational modifications. We calculate the tracer‐to‐tracee ratio of labelled to unlabelled amyloid and tau to determine rate of pathological accumulation of these proteins. Using a 2‐compartment model we establish the half‐life of tau in brain tissue.Result: We collected cortical brain biopsies from individuals with suspected NPH (n = 6), labelled between 4.25 hours to 133 days prior to surgery; 4 out of 6 individuals had amyloid plaques (range 1‐25 plaques/mm2). These individuals had mild cognitive impairment. Cored plaques showed characteristic localization of Aβ1‐40 and Aβ 3pE‐40 in the core while x‐42 species including 1‐42, 4‐42 and 3pE‐42 showed a more homogenous distribution across both plaque core and diffuse/immature plaque periphery (Figure 1, 2). We did not detect incorporation of labelled amyloid in any subject using IP‐MS or MALDI. We detected labelled tau in brain homogenate as early as 4.25 hours after label administration. The half‐life of tau in human brain was calculated to be 26.85 days.Conclusion: Our study provides the first detailed chemical characterisation of AD pathology in living human brain giving insights into plaque composition, age and tau dynamics.


  • Open Access

    CSF neurofilament light chain profiling and quantitation in neurological diseases

    by Claire A Leckey, John B Coulton, Tatiana A Giovannucci, Yingxin He, Aram Aslanyan, Rhiannon Laban, Amanda Heslegrave, Ivan Doykov, Francesca Ammoscato, Jeremy Chataway, et al.

    Neurofilament light chain is an established marker of neuroaxonal injury that is elevated in CSF and blood across various neurological diseases. It is increasingly used in clinical practice to aid diagnosis and monitor progression and as an outcome measure to assess safety and efficacy of disease-modifying therapies across the clinical translational neuroscience field. Quantitative methods for neurofilament light chain in human biofluids have relied on immunoassays, which have limited capacity to describe the structure of the protein in CSF and how this might vary in different neurodegenerative diseases. In this study, we characterized and quantified neurofilament light chain species in CSF across neurodegenerative and neuroinflammatory diseases and healthy controls using targeted mass spectrometry. We show that the quantitative immunoprecipitation–tandem mass spectrometry method developed in this study strongly correlates to single-molecule array measurements in CSF across the broad spectrum of neurodegenerative diseases and was replicable across mass spectrometry methods and centres. In summary, we have created an accurate and cost-effective assay for measuring a key biomarker in translational neuroscience research and clinical practice, which can be easily multiplexed and translated into clinical laboratories for the screening and monitoring of neurodegenerative disease or acute brain injury.